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Purpose: The Tyr402His variant of complement factor H (CFH) is associated with age-related macular degeneration
(AMD) in several populations. Our aim was to evaluate  if this  single  nucleotide  polymorphism (SNP) is  associated
with AMD in the Israeli population and see if it underlies heterogeneity in clinical manifestation and responses to
photodynamic therapy (PDT), which characterize neovascular AMD (NVAMD).
Methods: Genotyping for the Tyr402His variant was performed in 240 NVAMD patients  (78.1±7 age range) and 118
controls (70.8±8.2 age range). Genotyping was correlated with clinical characteristics and treatment parameters in
sequential 131 NVAMD patients who underwent PDT.
Results: TheTyr402His coding allele was associated with NVAMD in the Israeli population: odds ratio (OR)=1.9; 95%
confidence interval (CI)=1.3–2.6; p=0.0002. Homozygosity for this variant was associated with an OR of 3.4 (95% CI:
1.7–6.8) for having AMD. There was no association among this SNP and age of onset of NVAMD, gender, neovascular
lesion size, initial or final visual acuity, and number of PDT sessions required.
Conclusions: In accordance with findings from the majority of previous study populations, the Tyr402His variant of CFH
is associated with NVAMD in Israel. However, heterogeneity in clinical manifestations of NVAMD and in its response
to PDT is not underlined by this CFH variant and may be accounted for by other genetic and environmental factors.
Genetic factors play a strong role in the pathogenesis of
age related macular degeneration (AMD). While variations in
the sequence of several genes have been associated with AMD
in recent years [1], single nucleotide polymorphism (SNP) in
the gene for complement factor H (CFH) appears to be one of
the most consistent and important genetic risk factors for
AMD [2-8].
The Tyr402His variant of CFH (encoded by the C allele of
rs1061170 SNP) has been found to be associated with AMD
in  several  populations  worldwide  [3,5,6,9,10],  but  its
association with AMD in the Israeli population is unknown.
Subsequently,  additional  variants  in  both  coding  and
noncoding regions of the CFH gene, which are associated with
either increased or decreased, risk for developing AMD, have
been identified [11,12]. In view of CFH known function in
maintaining homeostasis of the complement system combined
with  evidence  for  involvement  of  inflammation  in  the
pathogenesis of AMD, it is likely that altered function of CFH
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variants affecting inflammatory response may account for its
association with the disease [13].
While genetic factors such as SNPs in CFH may increase
the likelihood of an individual to develop AMD, it is unclear
if these genetic factors also underlie variations in the clinical
manifestations  of  neovascular  AMD  (NVAMD)  such  as
variable age of onset, neovascular lesion size, visual acuity,
and response to therapy. Recent studies have suggested that
homozygosity  for  the  Tyr402His  variant  of  CFH  may  be
associated with classic or predominantly classic choroidal
neovascularization  (CNV)  lesion  type  according  to
fluorescein  angiography  [14-16],  and  with  response  to
bevacizumab  therapy  [17].  Conflicting  evidence  were
reported with respect to the association of the same variant
and response to photodynamic therapy (PDT) [15,18].
To  further  assess  this  issue  we  first  evaluated  the
association among NVAMD and the Tyr402His CFH variant
in  the  Israeli  population.  We  then  studied  the  correlation
among this variant, phenotype, and outcome following PDT.
METHODS
The study included 240 NVAMD patients recruited from four
retina clinics in Israel and 118 unaffected controls who were
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1829evaluated for routine eye examination, or for pathologies other
than  AMD,  in  the  Department  of  Ophthalmology  of  the
Hadassah–Hebrew University Medical Center in Jerusalem,
Israel. Institutional Ethics Committee approval was obtained
for the study, and each patient signed an informed consent
form.  AMD  was  diagnosed  and  graded  according  to  the
AREDS  trial  classification  [19].  Inclusion  criteria  for  the
control group included age over 60 years, clear media which
enabled ophthalmoscopy, and absence of intermediate size
drusen, multiple small drusen, or retinal pigment epithelial
abnormalities.
The female to male ratio was balanced between AMD
patients and controls. The mean age in the controls (70.8±8.2)
was lower than that of AMD patients (78.1±7.6, p<0.05, t-
test). The control group included 10 Arabs, 40 Sephardic
Jews, and 67 Ashkenazi Jews, while the study group included
7  Arabs,  73  Sephardic  Jews,  and  154  Ashkenazi  Jews
(p=0.047, χ2 test). The ethnicity of one individual from the
control  group  and  six  NVAMD  patients  was  unknown.
Median follow-up of NVAMD patients having PDT was 16
months (range 1–156 months).
Detailed  clinical  information  was  available  on  a
sequential subgroup of 131 NVAMD patients (of the 240
patients enrolled in the study), who were treated with PDT at
the  Hadassah–Hebrew  University  Medical  Center.  These
patients were included in the phenotype-genotype analysis.
Fluorescein  angiograms  of  these  NVAMD  patients  were
reviewed by retina specialists (I.C., E.B., I.H., and E.A.) who
were masked with respect to genotyping results. CNV was
classified as classic, predominantly classic, minimally classic,
or  occult  based  on  the  guidelines  of  the  Macular
Photocoagulation  Study  Group  [20].  Retinal  angiomatous
proliferation (RAP) lesions were classified as occult lesions.
Review of the entire group of patients was also performed in
a  masked  fashion  (with  respect  to  previous  lesion  type
classifications and to genotypes) by one of the investigators
(I.C.). There was agreement in 83.4% of cases between this
investigator  and  the  classification  by  the  treating  retina
specialist  (kappa  measurement  of  agreement=0.68;
p<0.0001). Classification according to the retina specialist
which  review  the  entire  cohort  was  used  for  statistical
analysis. The standard PDT protocol for NVAMD was applied
[21].
Genotyping for the rs1061170 SNP on the gene for CFH
was performed using iPLEXTM chemistry on a matrix-assisted
laser  desorption/ionization  time-of–flight  (MALDI-TOF)
mass spectrometer (Sequenom Inc., San Diego, CA).
Statistical analysis was performed using the SPSS (SPSS,
Chicago, IL) and Instat software (GraphPad, San Diego, CA).
Logistic regression and χ2 tests were applied to assess odds
ratios, confidence intervals, and significance.
Based  on  the  number  of  individuals  included  in  the
analysis, this study had 85% power for identification of an
association  between  genotypes  and  lesion  type  in  the
magnitude that was described by Brantley and colleagues
[14]. Our study also had 94% power for identification of an
association between genotypes and visual acuity following
PDT in the magnitude described by Brantley and colleagues
[22].
RESULTS
The  rs1061170  CFH  SNP  was  in  Hardy–Weinberg
equilibrium. Distribution of the genotypes was significantly
different between NVAMD patients and controls (p=0.00047,
χ2 test). Homozygotes for the C allele of rs1061170 had an
odds ratio (OR) of 3.4 and a 95% confidence interval (CI) of
1.7–6.8. Heterozygotes had an OR of 2.1 (95% CI 1.3 −3.4)
for  having  NVAMD  compared  with  homozygotes  for  the
wild-type  allele,  respectively  (Table  1).  Combined,
individuals  either  homozygous  or  heterozygous  for  the  C
allele had an OR of 2.4 (95% CI 1.5–3.8, p=0.0005) compared
with  individuals  homozygous  for  the  T  allele  for  having
AMD. Analysis according to distribution of the C and T alleles
showed  similar  findings  (Table  1).  We  evaluated  if  the
absence  of  drusen  in  some  of  the  NVAMD  cases  could
introduce  bias  and  reduce  the  strength  of  the  associated
between rs1061170 and NVAMD in our study.
Of 240 NVAMD patients, 234 had drusen, three did not
have drusen, and in three patients the presence of drusen could
not be confirmed due to bilateral large exudative lesions. The
association between NVAMD patients with drusen and the C
allele was similar in magnitude to the association between the
entire NVAMD cohort and the same variant (data not shown).
A subgroup analysis was performed to evaluate if the
rs1061170  SNP  is  associated  with  NVAMD  among
Ashkenazi  and  Sephardic  Jews.  There  were  too  few
individuals of Arab origin in our cohort to evaluate for an
association between rs1061170 and NVAMD in this ethnic
group. The Tyr402His variant was associated with NVAMD
among Ashkenazi Jews (p=0.003, χ2 test). There was a trend
toward such an association among Sephardic Jews (p=0.19,
χ2). Analysis according to alleles showed similar findings
(Table 1).
Following the establishment of an association between
rs1061170  and  NVAMD  in  our  population,  we  have
correlated genotypes with clinical characteristics of NVAMD
and with response to PDT. Included in this analysis were 131
sequential  NVAMD  patients,  who  were  treated  in  the
Department  of  Ophthalmology  of  the  Hadassah  Medical
Center and who were characterized in terms of phenotype and
response to PDT. There were no associations found between
rs1061170 genotypes and clinical or demographic parameters
of  NVAMD  patients  including  age,  gender,  AMD  family
history, lesion size, initial and final visual acuity, and number
of PDT sessions required.
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lesion type when classified into classic (including pure classic
and  predominantly  classic)  or  occult  (pure  occult  and
minimally classic) lesions (Table 2). Yet, while heterozygotes
had a 2.5-fold higher prevalence of occult than classic lesions,
the  proportion  of  such  lesions  was  nearly  balanced  in
homozygotes for either the T or C alleles (Table 2). Patients
were then classified to those carrying the C allele (either
homozygotes  or  heterozygotes)  and  those  that  are
homozygotes for the T allele. Lesion type was not associated
with this classification (p=0.23). Analysis according to four
categorizes (classic, predominantly classic, minimally classic,
occult) showed similar findings (data not shown). There was
no association between genotypes and response to PDT when
assessed  separately  in  classic  (including  predominantly
classic) and occult (including minimally classic) lesions.
DISCUSSION
We found that the Tyr402His variant of CFH is associated
with NVAMD in the Israeli population. Association of the
Tyr402His variant of CFH with AMD has been described in
several  populations  worldwide  [3,6,9,10,23-26],  but  it
appears to be less common in Chinese [27], and is not present
in  Japanese  [28-30].  The  composition  of  the  Israeli
population,  which  was  included  in  the  present  study,  is
different  from  previously  studied  populations.  Our  study
group is composed of several ethnic groups, which may be
classified into three main groups: Arabs, Sephardic Jews, and
Ashkenazi Jews. Our data suggest that the Tyr402His variant
is  associated  with  NVAMD  in  Ashkenazi  Jews.  A  trend
toward such an association was observed among Sephardic
Jews, and the distribution of genotypes in this group suggests
that the magnitude of the association of the Tyr402His variant
is similar in Ashkenazi and Sephardic Jews. There were too
few Arab NVAMD patients in this study to determine if the
Tyr402His variant is associated with NVAMD in this ethnic
group. The relatively low number of Arabs in the study group
compared with the control group may stem from the rarity of
NVAMD in the Arab population in our referral area [31].
A  stronger  association  between  NVAMD  and  the
Tyr402His  variant  compared  with  the  one  we  have
documented was demonstrated in certain but not in all cohorts
[5,23,32,33].  For  example,  Haines  and  colleagues  [5]
described an OR of 2.45 for heterozygotes and an OR of 3.33
for  homozygotes  of  the  Tyr402His  variant  among  AMD
patients. These respective ORs increased to 3.45 and 5.57
among patients with NVAMD [5]. Yet, a recent meta-analysis
of 14 studies revealed an average OR of 2 for the association
between the C allele encoding the Tyr402His variant and
AMD, a value similar to the one we detected (OR=1.9) [34].
Thus,  it  is  unclear  if  there  are  differences  strength  of
association between the Tyr402His variant and AMD among
Israeli population and white populations.
Inflammation is thought to play a role in CNV [35-37],
and an altered inflammatory response associated with the
TABLE 1. THE FREQUENCY OF ALLELES AND GENOTYPES OF COMPLEMENT FACTOR H RS1061170 SNP IN ISRAELI NVAMD PATIENTS AND
UNAFFECTED CONTROLS
Population  Age-related macular
degeneration







Ashkenazi Jews 147/161 (47.7%/52.3%) 87/47 (64.9%/35.1%) 0.0009 2 (1.3–3.1)
Sephardic Jews 74/72 (50.6%/49.4%) 51/29 (63.7%/36.3%) 0.07 1.7 (1–3)
By genotype
Entire Population
          TT 55 (22.9%) 49 (41.5%) 0.00047
          TC 127 (52.9%) 54 (45.8%)   2.1(1.3–3.4)
          CC 58 (24.2%) 15 (12.7%)   3.4 (1.7–6.8)
Ashkenazi Jews
          TT 33 (21.4%) 27 (40.3%) 0.003
          TC 81 (52.6%) 33 (49.3%)   1.9 (1–3.8)
          CC 40 (26%) 7 (10.4%)   13.9 (3.1–62.5)
Sephardic Jews
TT 18 (24.7%) 17 (42.5%) 0.19
TC 38 (52%) 17 (42.5%)   1.8 (0.7–1.9)
CC 17 (23.3%) 6 (15%)   2.8 (0.9–9.5)
Comparison of the frequency (%) of complement H  rs1061170  variants between NVAMD patients and controls in the entire
Israeli population and in the Ashkenazi and Sephardic subpopulations. Increased prevalence of the C variant was associated
with the disease in the Ashkenazi subpopulation. CI- confidence interval, OR- odds ratio.
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as affect its response to therapy. In our study, this potential
effect of Tyr402His variant on NVAMD had no apparent
clinical  implications.  Diverse  clinical  characteristics  of
NVAMD among patients such as age of onset, initial visual
acuity, lesion size, and response to PDT were not attributable
to the Tyr402His variant.
An  increased  prevalence  of  occult  CNV  among
heterozygotes was observed in our study, but the importance
of this association is unclear. Homozygotes for the wild-type
and risk alleles had a similar prevalence of occult and classic
lesions, and there was no association between lesion type and
the  Tyr402His  variant  when  carriers  for  the  variant
(homozygote and heterozygotes combined) were compared
with  homozygote  for  the  wild-type  allele.  An  association
between the Tyr402His variant and classic CNV lesion type
was previously reported in three cohorts, while two other
studies  failed  to  identify  such  an  association.  One  study
reported that the same variant may be associated with occult
lesion type [14-17,38,39]. Combined, these data suggest that
the Tyr402His variant does not have a major contribution for
determination of lesion type. Additional studies of different
populations are required to determine if the Tyr402His variant
is indeed associated with lesion type and if such an association
is population-specific.
Revealing such pharmacogenetic interactions in AMD
may facilitate improved treatment selection for the individual
patient and provide important insight into the pathogenesis of
the disease. Interactions between the Tyr402His variant and
PDT  or  anti-vascular  endothelial  growth  factor  (VEGF)
compounds, if they exist, should be reflected in parameters
such as the visual outcome following applications of these
therapies  or  number  of  treatment  sessions  required.
Goverdhan and colleagues [15] reported that the degree of
visual  loss  following  PDT  was  significantly  higher  in
homozygotes for the Tyr402His variant among 27 NVAMD
patients who had PDT. By contrast, Brantley and colleagues
found that among 69 NVAMD patients, the post-PDT visual
acuity was better in homozygotes for the Tyr402His variant
compared with homozygotes for the wild-type allele [22].
However, in accordance with our findings in 131 NVAMD
patients,  Seitsonen  and  colleagues  [40]  did  not  find  an
association between the Tyr402His variant and response to
PDT among 88 NVAMD patients. Thus, should interactions
between PDT and the Tyr402His variant exist, they may be
population-specific. While the association between PDT and
Tyr402His variant is still unclear, Brantley and colleagues
[17] reported that among 86 NVAMD patients treated with
bevacizumab  injections,  homozygotes  for  the  Tyr402His
variant had worse visual outcome. Thus, pharmacogenetic
interactions in NVAMD may exist and may potentially be
treatment- and perhaps population-specific.
Elucidating  the  genetic  or  environmental  factors  that
underlie heterogeneity in the manifestation and response into
treatment of NVAMD will provide important insight to the
pathogenesis of the disease and may enable selection of the
most appropriate therapy for each patient. Our data did not
demonstrate  a  major  contribution  of  the  Tyr402His
polymorphism in the course of NVAMD and its response to
therapy  in  the  context  of  other  genetic  backgrounds  and
environmental conditions.
TABLE 2. EVALUATION FOR ASSOCIATION AMONG CLINICAL PARAMETERS IN PATIENTS WITH NVAMD AND COMPLEMENT FACTOR H RS1061170 VARIANTS
Parameter    rs1061170 genotype
TT CC TC P
Gender (female/male) 13/12 10/25 37/34 0.057
Lesion type (classic/occult)* 14/11 16/19 20/51 0.027
Family History of AMD (yes/no) # 2/23 6/21 11/47 0.353
Age (mean ± SD, in years) 78.4±9.63 78.5±7.44 78.68±7.89 0.989
Initial VA (mean±SD, logMAR) 1.1±0.82 1.15±0.91 1±0.71 0.659
Lesion size (mean±SD, in µm) 3965.7±1711.4 4074.4±1386.9 3580.1±1019.1 0.207
Number of PDT sessions 2.76±2.47 2.06±1.92 2.06±1.56 0.240
Final VA (mean±SD, logMAR) 1.53±0.98 1.53±0.95 1.35±0.84 0.547
Analysis for potential association among the wild type (T) and risk (C) alleles of the rs1061170 single nucleotide polymorphism
in complement factor H and clinical parameters in patients with NVAMD is presented. There was no association between
homozygosity for the risk allele and the factors which were evaluated. The asterisk represents that despite the presence of an
association among heterozygosity and lesion type, there was no association between lesion type and rs1061170 when comparing
lesion type in patients with TC and CC genotype combined with lesion type in patients with TT genotype, or when comparing
lesion type between patients with the TT and CC genotypes. The following abbreviations and symbols are used: visual acuity
(VA), photodynamic therapy (PDT); the sharp(hash mark) represents family history for age-related macular degeneration could
not be reliably assessed for 21 patients.
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